Selected article for: "observational study and protective factor"
Author: Demichelis-Gómez, Roberta; Alvarado-Ibarra, Martha; Vasquez-Chávez, Jule; Delgado-López, Nancy; Gómez-Cortés, Cynthia; Espinosa-Bautista, Karla; Cooke-Tapia, Ana; Milán-Salvatierra, Andrea; Gómez-De León, Andrés; Lee-Tsai, Yu Ling; Rosales-López, Daniel; Cabrera-García, Álvaro; Amador-Medina, Fabián; Córdoba-Ramírez, Alejandra; Murrieta-Álvarez, Iván; Solís-Poblano, Juan Carlos; Apodaca-Chávez, Elia; Rangel-Patiño, Juan; Álvarez-Vera, José Luis; Arana-Luna, Luara; De la Peña-Celaya, José Antonio; Espitia-Ríos, María Eugenia; Hernández-Ruiz, Eleazar; Pérez-Zúñiga, Juan Manuel; Peña-López, Estefanía; González-Rivera, Rosa; García-Leyva, María Fernanda; Tejeda-Romero, Mónica; Cruz-Rico, Jorge; Balderas-Delgado, Carolina; Ruíz-Argüelles, Guillermo J.; Gómez-Almaguer, David
Title: Treating Acute Leukemia During the COVID-19 Pandemic in an Environment With Limited Resources: A Multicenter Experience in Four Latin American Countries
  • Cord-id: 8x7eyxlv
  • Document date: 2021_4_23
    • ID: 8x7eyxlv
    Snippet: PURPOSE: The COVID-19 pandemic is a colossal challenge for global health; nonetheless, specific subgroups face considerably higher risks for infection and mortality. Among patients with malignant diseases, those with hematologic neoplasms are at a higher risk for poor outcomes. The objective of this study was to register treatment modifications associated with the COVID-19 pandemic and their short-term consequences in Latin America. METHODS: Multicenter, prospective, observational, cohort study
    Document: PURPOSE: The COVID-19 pandemic is a colossal challenge for global health; nonetheless, specific subgroups face considerably higher risks for infection and mortality. Among patients with malignant diseases, those with hematologic neoplasms are at a higher risk for poor outcomes. The objective of this study was to register treatment modifications associated with the COVID-19 pandemic and their short-term consequences in Latin America. METHODS: Multicenter, prospective, observational, cohort study including patients older than 14 years from 14 centers in four countries (Mexico, Peru, Guatemala, and Panama) who had a confirmed diagnosis of acute leukemia, and who were undergoing active treatment since the first COVID-19 case in each country until the cutoff on July 15, 2020. RESULTS: We recruited 635 patients. Treatment modifications because of the COVID-19 pandemic were reported in 40.8% of cases. The main reason for such modifications was logistic issues (55.0%) and the most frequent modification was chemotherapy delay (42.0%). A total of 13.1% patients developed COVID-19 disease, with a mortality of 37.7%. Several factors were identified as independently associated with mortality, including a diagnosis of acute myeloid leukemia (odds ratio 2.38 [95% CI, 1.47 to 3.84]; P < .001), while the use of telemedicine was identified as a protective factor (odds ratio 0.36 [95% CI, 0.18 to 0.82]; P = .014). CONCLUSION: These results highlight the collateral damage of COVID-19 in oncology patients.

    Search related documents:
    Co phrase search for related documents
    • active treatment and acute leukemia diagnosis: 1
    • active treatment and acute leukemia patient: 1
    • active treatment and acute lymphoblastic leukemia: 1, 2, 3, 4
    • active treatment and acute myeloid leukemia: 1, 2, 3, 4, 5, 6
    • active treatment and acute promyelocytic leukemia: 1
    • active treatment and acute respiratory illness: 1, 2, 3
    • active treatment and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute leukemia and logistic regression: 1, 2, 3, 4
    • acute leukemia diagnosis and logistic regression: 1
    • acute lymphoblastic leukemia and logistic regression: 1
    • acute myeloid leukemia and logistic regression: 1
    • acute respiratory illness and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25